Season Two of Surfing The NASH Tsunami

S2-E40 – Discussing Comprehensive Care Models For NAFLD

Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join the Surfers to discuss their recent paper, “Defining Comprehensive Models of Care for NAFLD.” In this vitally important paper, the authors researched care models around the world to find the ones that work best, and then developed eight foundational recommendations for co-ordinated NAFLD care centers.

S2-E38.2 – Building a Culture That Encourages Patient Participation

Global Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer Dr. James Powell and Global Liver Institute Director of NASH programs Jeff McIntyre in an eye-opening discussion about what it takes to recruit diverse patients into clinical trials.

S2-E38.1 – Motivating Underserved Patients To Participate In Clinical Trials

Global Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer Dr. James Powell and Global Liver Institute Director of NASH programs Jeff McIntyre in an eye-opening discussion about what it takes to recruit diverse patients into clinical trials.

S2-E38 – Increasing Diversity In The Clinical Trial Patient Population

Global Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer Dr. James Powell and Global Liver Institute Director of NASH programs Jeff McIntyre in an eye-opening discussion about what it takes to recruit diverse patients into clinical trials.

S2-E37.2 – NASH Diagnostics Provide A Natural Brake On Overly Broad Adoption Of NASH Drugs

Jörn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia markets. This conversation focuses on the unique challenges posed by the complexity of NASH and NAFLD and the current state of diagnostic testing. It has been common for industry advocates and financial analysts to discuss the potential for the NASH/NAFLD drug market in comparison to the statin market, but this overlooks differences in the conditions they treat (NASH vs. hypercholesterolemia), the diagnostics available and the health economic environment.

S2-E32 – Leaders Provide Perspectives on #ILC2021

Incoming EASL Secretary General Prof. Thomas Berg, Global Liver Institute President and CEO Donna Cryer and Genfit Head of Global Diagnostics Suneil Hosmane share their unique perspectives on Digital ILC 2021 with Roger Green.

Subscribe for free. New podcasts Wednesday Evening / Thursday Morning.

Apple
Spotify
Google
Stitcher
Buzzsprout
YouTube
SoundCloud